Pam Zehr, 319-353-8914
Participants in this study have been diagnosed with cancer and have advanced nonfunctional neuroendocrine tumors. This is a voluntary study to find out if the drug everolimus (Afinitor®) is sage and has beneficial effects in people who have this disease. About 279 patients will join in this study at around 120 research clinics in several countries around the world.
Please help us improve your experience on our website by completing a brief survey
Yes, I'll give feedback No, Thanks
Your browser does not support iframes.